SNA™ Gene Regulation Therapeutics

Learn More

About Us

AuraSense Therapeutics' uniquely engineered Spherical Nucleic Acid (SNA™) constructs possess unparalleled biocompatibility and versatility as therapeutics. They hold great promise for combating the most threatening diseases, including heart disease, cancer, skin conditions and bacterial infection.

SNA™ constructs overcome one of the most difficult obstacles to gene regulation:  safe and effective delivery into cells and tissues.  SNA™ constructs exhibit high stability, high binding specificity, and unparalleled transfection efficiency into numerous cell and tissue types.  Needing no carriers or transfection agents, they provoke minimal immune response and no known toxicity.

SNA™ technology originated in the lab of Professor Chad A. Mirkin at the Northwestern University International Institute for Nanotechnology.  The Company's scientific founders and their developments have been the subject of over 60 international and national awards, over 500 publications, and over 450 patents.

Latest News

  • Nanoparticles Offer 'Open Sesame' Keys to New Drugs and Vaccines

    April 20, 2012go

  • Chicago startups Buzz Referrals, AuraSense get VC funds from state

    January 31, 2012go

  • Chad Mirkin Recognized for the Invention of Spherical Nucleic Acid Technology

    January 2, 2012go

  • AuraSense Therapeutics Secures Series B Equity Investment

    December 21, 2011go

  • Hitting The ‘Off’ Switch On Antibiotic Resistance

    December 2, 2011go